Monthly Archives: January 2023

Pegcetacoplan, a targeted C3 inhibitor, has shown promising results in the treatment of rare diseases. With recent approvals for paroxysmal nocturnal hemoglobinuria (PNH) and ongoing clinical trials for other complement-mediated disorders, pegcetacoplan holds great potential for improving patient outcomes. This … Continue reading →